Présentation de l'entreprise
Artivion, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it manufactures, processes, and distributes implantable human tissues and prosthetic heart valves globally. The company's product portfolio includes On-X prosthetic aortic and mitral heart valves, On-X ascending aortic prosthesis, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures, and pyrolytic carbon coatings designed for cardiac applications. This enterprise maintains a substantial operational scale with a reported market capitalization of $1.75 billion and an annual revenue based on the trailing twelve months of $441.33 million. Furthermore, the organization employs approximately 1,800 individuals to support its worldwide distribution network. The valuation of $1.75 billion relative to the annual revenue of $441.33 million indicates that the market assigns a significant premium to the company's future growth potential in the medical device space, while the revenue figure reflects a consistent stream of income generated from the sale of these specialized cardiovascular technologies. The employment count of 1,800 underscores the substantial infrastructure required to maintain global supply chains and regulatory compliance for implantable medical devices.
Santé financière
The company reported a trailing twelve-month revenue of $441.33 million, which generated a net income of $9.76 million and an EBITDA of $53.80 million. The substantial gap between the EBITDA of $53.80 million and the net income of $9.76 million reveals a significant cost structure driven by non-operating expenses, including substantial interest costs associated with the company's debt obligations. Operating free cash flow stands at -$20,097,624, indicating that current cash outflows for capital expenditures and working capital requirements exceed operating cash generation, which limits immediate financial flexibility for share buybacks or aggressive dividend payments. Gross margin is reported at 64.4%, reflecting the high value of the specialized medical devices sold relative to the cost of goods sold. Operating margin sits at 8.1%, while profit margin is 2.2%, illustrating that after accounting for operating expenses and interest, the portion of revenue converting to bottom-line profit is relatively thin. The company holds $64.91 million in cash against total debt of $258.51 million, resulting in a debt-to-equity ratio of 57.67, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high leverage, the current ratio of 3.53 suggests strong short-term liquidity, indicating that the company holds ample current assets to cover its short-term liabilities. Return on equity is 2.7% and return on assets is 2.3%, metrics that reveal management effectiveness is currently low, as the company generates minimal returns relative to the equity invested and the total asset base utilized.
Évaluation de la valorisation
The trailing twelve-month price-to-earnings ratio is 171.71, whereas the forward P/E ratio is significantly lower at 31.19. This stark difference between the trailing and forward multiples implies that the market expects earnings to increase dramatically in the future to justify the current stock price relative to expected future profits. The price-to-book ratio stands at 3.85, indicating that the market values the company at nearly four times its book value, suggesting a premium assigned to the intangible value of its intellectual property and market position. Alternative valuation metrics such as the price-to-sales ratio of 3.96 and an EV/EBITDA of 35.70 suggest that investors are willing to pay a premium for revenue and earnings growth even in the absence of current profitability. The stock trades between a 52-week high of $48.25 and a 52-week low of $21.97. Assuming the current trading price aligns with the midpoint or recent market behavior, the valuation sits within a range that reflects the high volatility typical of small-cap biotech and medical device firms. The beta value is 1.62, which indicates that the stock price is significantly more volatile than the broader market, amplifying both potential gains and losses during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is 19.2%, while earnings growth for the trailing twelve months is listed as N/A due to the low net income relative to revenue. The absence of reported earnings growth alongside strong revenue expansion suggests that profitability is currently being suppressed by high fixed costs or interest expenses rather than a lack of top-line sales momentum. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. Instead, the firm reinvests its earnings and cash flow into research, development, and operational expansion to fund future growth initiatives rather than providing current income to investors. The overall growth and income profile is characterized by robust revenue expansion without dividend support, positioning the equity as a growth-oriented investment rather than an income-generating asset. This strategy relies on the expectation that future earnings will eventually improve to support shareholder returns through other mechanisms or by increasing the return on invested capital.